Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model [0.03%]
健康受试者和BRAF V600突变固有肿瘤患者中恩考芬尼的群体药代动力学研究：半机制自身诱导模型
Derek Z Yang,Erik M Hahn,Joseph Piscitelli et al.
Derek Z Yang et al.
Background and objective: Encorafenib is a potent and selective adenosine triphosphate-competitive BRAF V600-mutant kinase inhibitor. Encorafenib is approved for multiple indications in combination with binimetinib or cet...
Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods [0.03%]
基于模型的蛋白激酶抑制剂精准用药研究：模型平均及扁平先验方法评估
Félicien Le Louedec,Laura Morvan,Loïc Mourey et al.
Félicien Le Louedec et al.
Background and objectives: Therapeutic drug monitoring of protein kinase inhibitors (PKIs) usually relies on the measure of a single trough concentration at steady-state (Cmin,ss). When the sampling time differs from the ...
Predicting Cumulative Neonatal Sodium Benzoate Exposures During Breastfeeding with Physiologically Based Pharmacokinetic Modelling [0.03%]
基于生理的药代动力学模型预测母乳喂养期间新生儿累积苯甲酸钠暴露量
Shirley Wang,Abdullah Hamadeh,Paola Mian et al.
Shirley Wang et al.
Background and objective: Sodium benzoate (SB) is used as a second-line therapy to treat rare urea cycle disorders (UCDs) in paediatric and adult patients. However, lactation data for SB do not exist, leading to uncertain...
Utilization of Apixaban Pharmacokinetics for Dose Optimization in High-Risk Elderly Patients [0.03%]
利用阿哌沙班药代动力学特性优化高危老年患者给药剂量的研究
Rachel Goldstein,Khaled Sandouka,Lana Zighan et al.
Rachel Goldstein et al.
Background and objective: Direct oral anticoagulants have largely replaced vitamin K antagonists, for example, warfarin, because of their favorable safety profile and predictable pharmacokinetics, with apixaban being the ...
Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase [0.03%]
利用模型指导的药物开发预测阿舒米尼在慢性期慢性髓性白血病二线治疗中的疗效
Sherwin K B Sy,Deok Yong Yoon,Yiqun Yang et al.
Sherwin K B Sy et al.
Background and objectives: The efficacy of asciminib was proven in newly diagnosed (first-line, 1L) patients with Philadelphia-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) and in patients treated with a...
Single Saliva Sample Model-Informed Precision Dosing of Levofloxacin for Multidrug-Resistant Tuberculosis [0.03%]
基于模型的左氧氟沙星精准治疗耐多药结核病的单份唾液样品方法
Thi A Nguyen,Tri P Nguyen,Anh T Nguyen et al.
Thi A Nguyen et al.
Background and objectives: Levofloxacin is an essential drug in multidrug-resistant tuberculosis (MDR-TB) treatment, but high pharmacokinetic variability necessitates therapeutic drug monitoring (TDM) to optimise exposure...
Pär Nordell,Rasmus Jansson-Löfmark,Peter Gennemark
Pär Nordell
Introduction: Peptide-based therapeutics represent a rapidly expanding class of drugs. Endogenous peptides typically exhibit short elimination half-lives due to proteolytic cleavage and renal filtration. However, modifica...
Nomograms for Therapeutic Drug Monitoring of High-Dose Amikacin in Critically Ill Patients: Insights from a Population Pharmacokinetic Analysis and Dosing Simulation [0.03%]
危重病人的高剂量阿米卡星治疗药物监测的图表：来源于人群药代动力学分析和给药模拟的新见解
Thi Cuc Nguyen,Dinh Van Le,Hoang Anh Nguyen Jr et al.
Thi Cuc Nguyen et al.
Background and objective: This study evaluated the probability of pharmacokinetic/pharmacodynamic efficacy target attainment and developed a dosing interval identification nomogram to minimize toxicity risks of high-dose ...
Pharmacokinetics, Pharmacodynamics and Safety of Fultagliptin Benzoate Tablets, a DPP-4 Inhibitor, in Patients With Varying Degrees of Renal Insufficiency and Matched Healthy Volunteers: A Phase I Clinical Trial [0.03%]
一项评价磷酸伏格列汀片在不同程度肾功能不全患者及健康受试者中的药代动力学、药效学和安全性的I期临床试验
Yue Chen,Chao Hu,Xiaotao Cao et al.
Yue Chen et al.
Background: DPP-4 inhibitors are a class of oral hypoglycemic drugs commonly used in the treatment of type 2 diabetes mellitus (T2DM). Fultagliptin benzoate is a novel and high-selective DPP-4 inhibitor. The renal excreti...
Evaluation and Improvement of Specialized Vancomycin Pharmacokinetic Models for Pediatric Cardiovascular Intensive Care Unit and Pediatric Oncology Patients [0.03%]
儿科心血管重症监护病房和肿瘤科患者万古霉素药代动力学模型的评估与改进
Michael G McCarthy,Ron J Keizer,Jasmine H Hughes
Michael G McCarthy
Background and objective: Dose optimization of vancomycin in distinct pediatric subpopulations is inherently complex due to altered vancomycin pharmacokinetics associated with certain conditions or circumstances, such as ...